期刊文献+

循环应用低剂量环磷酰胺联合白细胞介素-2对乳腺癌荷瘤小鼠调节性T细胞及生存期影响 被引量:2

Influence of Cyclical Administration with Low-dose Cyclophosphamide and Interleukin-2 on Regulatory T Cells of Murin Breast Cancer Model and Its Life Span
下载PDF
导出
摘要 目的了解循环应用小剂量环磷酰胺(CTX)联合白细胞介素-2(IL-2)对4T1Balb/c乳腺癌荷瘤小鼠调节性T细胞(Treg)及其生存期影响。方法通过皮下接种4T1乳腺癌细胞建立乳腺癌Balb/c荷瘤小鼠模型;荷瘤小鼠随机分为IL-2组、CTX组、IL-2+CTX组及对照组,在种瘤第10天开始对荷瘤小鼠分别经腹腔按方案给药,部分小鼠在末次给药后4天处死,流式细胞术检测小鼠脾脏中CD4+CD25+/CD4+调节性T细胞数量;余小鼠观察生存期。结果 IL-2组、CTX组、IL-2+CTX组及对照组调节性T细胞比例分别为26.00%±0.98%、11.30%±0.85%、20.15%±1.11%、17.50%±1.13%,组别之间差异均有显著性(P<0.05)。IL-2+CTX组小鼠最长存活57天,对照组小鼠最长存活46天,差异具有显著性(P<0.05)。结论 IL-2联合循环应用CTX将调节性T细胞持续维持在较低水平,从而延长小鼠生存期。 Objective To observe the influence of cyclical administration with Cyclophosphamide (CTX) and Inter- leukin-2 (IL-2) on regulatory T cells (Treg) of murine breast cancer model and its life span. Methods Murine breast cancer model was established by inoculating s. c. mice with 4T1 breast cancer tumor cell line. Tumor-bearing BALB/c mice were randomly divided into four groups : IL-2 group and CTX group and IL-2 + CTX group and control group. Mice in groups were injected intraperitoneally on schedule at the tenth day after tumor was established. Part of mice were sacrificed on day 4 after the last adminstration. We examined Regulatory T ceils ratio of spleen cells by flow cytometry. Others were observed for survival. Results The CD4 + CD25 +/CD4+ ration in spleens of IL-2 group, CTX group, IL-2 + CTX group and con- trol group were 26.00%± 0.98%, 11.30% ±0.85% ,20. 15% ± 1. 11%, 17.50% ± 1. 13% respectively. Significant differences were observed between each group( P 〈 0.05 ). The longest life span in IL-2 + CTX group and control group were 57 days and 46 days respectively, significant differences were observed between these groups. Conclusions Cyclical ad- ministration of low dose CTX keep Treg ratio which were expanded by IL-2 in a low level lead to a longer life span.
出处 《中南医学科学杂志》 CAS 2013年第4期353-356,共4页 Medical Science Journal of Central South China
关键词 环磷酰胺 白细胞介素-2 调节性T细胞 cyclophosphamide interleukin-2 regulatory T cell
  • 相关文献

参考文献15

  • 1d'Hennezel E, Kornete M, Piccirillo CA. IL-2 as a thera- peutic target for the restoration of Foxp3 regulatory T cell function in organ-specific autoimmunity:implications in pathophysiology and translation to human disease [ J ]. J Transl Med ,2010,8 : 113.
  • 2Shevach EM. Mechanisms of foxp3 T regulatory cell-me- diated suppression [ J ]. Immunity,2009,30 (5) :636-645.
  • 3Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [ J ]. Nat Med, 2004,10 (9) :942-949.
  • 4Ikezawa Y, Nakazawa M, Tamura C, et al. Cyclophospha- mide decreases the number, percentage and the function of CD25 CIM + regulatory T cells, which suppress induction of contact hypersensitivity [ J ]. J Dermatol Sci, 2005,39 (2) :105- 112.
  • 5Motoyoshi Y, Kminoda K, Saitoh O, et al. Different mecha- nisms for anti- tumor effects of low- and high- dose cyclo- phosphamide [ J]. Oncol Rep,2006,16( 1 ) : 141- 146.
  • 6Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T ceils expressing IL-2 receptor alpha-chains ( CD25 ). Breakdown of a sin- gle mechanism of self-tolerance causes various autoim- mune diseases [ J ]. J Immunol, 1995, 155 ( 3 ) : 1151-1164.
  • 7Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin- 10-secreting type 1 regulatory T ceils in rodents and hu- mans [ J ]. Immunol Rev, 2006,212 : 28-50.
  • 8Han Y, Guo Q, Zhang M, et al. CD69 CIM CD25- T cells, a new subset of regulatory T cells, suppressT cell proliferation through membrane-bound TGF-beta 1 [ J ]. J Immuno1,2009,182 ( 1 ) : 111-120.
  • 9Schabowsky RH, Madireddi S, Sharma R, et al. Targeting CIM CD25 FoxP3 regulatory T-cells for the augmen- tation of cancer immunotherapy [ J ]. Curr Opin Investig Drugs, 2007,8 ( 12 ) : 1002 - 1008.
  • 10于益芝,曹雪涛.调节性T细胞在肿瘤免疫和肿瘤免疫治疗中的作用[J].中国肿瘤生物治疗杂志,2010,17(1):1-6. 被引量:51

二级参考文献87

  • 1Gershon RK, Kondo K. Infectious immunological tolerance [J]. Immunology, 1971 , 21 (6) : 903-914.
  • 2Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes [ J ]. Immunology, 1970, 18 ( 5 ) : 723-737.
  • 3Fujimoto S, Greene M, Sehon AH. Immunosuppressor T cells in tumor bearing host [J]. Immunol Commun, 1975, 4(3):201- 217.
  • 4Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenie tumor [J]. J Exp Med, 1980, 151 ( 1 ) : 69-80.
  • 5Bursuker I, North RJ. Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity [J]. J Exp Med, 1984, 159(5) : 1312-1321.
  • 6North R J, Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I Ly-1-2- suppressor T ceils down-regulate the generation of Ly-1-2 + effector T cells [ J 1. J Exp Med, 1984, 159(5) : 1295-1311.
  • 7Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B. Autologous melanoma-induced activation of regulatory T ceils that suppress cytotoxic response [ J ]. J Immunol, 1990, 145(7) : 2359-2364.
  • 8Sakaguchi S, Sakaguehi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains ( CD25 ). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases [ J]. J Immunol, 1995, 155(3): 1151-1164.
  • 9Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 ( interleukin-2 receptor alpha) monoclonal antibody [ J ]. Cancer Res, 1999, 59(13): 3128-3133.
  • 10Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25 + CD4 + T cells : a common basis between tumor immunity and autoimmunity [ J]. J Immunol, 1999, 163 (10): 5211-5218.

共引文献53

同被引文献7

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部